Myriad Genetics buy DerAlmanach100000
Start price
23.11.25
/
100%
€6.30
Target price
23.11.28
-
Performance (%)
-42.22%
Price
13.04.26
€3.64
Summary
This prediction is currently active. The BUY prediction by DerAlmanach100000 for Myriad Genetics is performing very badly with a performance of -42.22%. This prediction currently runs until 23.11.28. The prediction end date can be changed by DerAlmanach100000 at any time. DerAlmanach100000 has 100% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Myriad Genetics | -10.784% | -10.784% |
| iShares Core DAX® | 3,02 % | 2,20 % |
| iShares Nasdaq 100 | 3,56 % | 1,33 % |
| iShares Nikkei 225® | 6,62 % | 5,71 % |
| iShares S&P 500 | 2,64 % | 1,01 % |
According to DerAlmanach100000 what are the pros and cons of Myriad Genetics for the foreseeable future?
Pros
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Very Future proof/growth oriented business model
Market Leader or Top 3
Cons
Comments by DerAlmanach100000 for this prediction
Stopped prediction by DerAlmanach100000 for Myriad Genetics
Myriad Genetics
Start price
Target price
Perf. (%)
€4.44
05.06.25
05.06.25
-
05.06.28
05.06.28
8.56%
06.08.25
06.08.25
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Myriad Genetics
Start price
Target price
Perf. (%)
€4.34
03.06.25
03.06.25
-
03.07.25
03.07.25
8.29%
04.06.25
04.06.25
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Myriad Genetics
Start price
Target price
Perf. (%)
€3.60
17.05.25
17.05.25
-
17.05.28
17.05.28
6.67%
28.05.25
28.05.25
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued